Citi analyst Amit Hazan downgraded Abbott Laboratories to Sell and lowered his price target for the shares to $68 from $72.
Wednesday, January 2, 2019
Baxter upgraded to Buy from Neutral at Citi
Citi analyst Amit Hazan upgraded Baxter International to Buy and raised his price target for the shares to $76 from $69.
Zimmer Biomet upgraded to Buy from Neutral at Citi
Citi analyst Amit Hazan upgraded Zimmer Holdings to Buy and raised his price target for the shares to $127 from $122.
Stryker upgraded to Outperform from In Line at Evercore ISI
https://thefly.com/landingPageNews.php?id=284232
Novartis downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novartis to Underweight with a price target of CHF 89. The analyst has concerns over the company’s pipeline and believes the shares are close to fair value.
Bayer downgraded to Neutral from Overweight at JPMorgan
Bayer downgraded to Neutral from Overweight at JPMorgan. JPMorgan analyst Richard downgraded Bayer to Neutral and lowered his price target for the shares to EUR 70 from EUR 100. The analyst believes 2019 will be another “messy year” for the company.
Lundbeck downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Lundbeck to Underweight and lowered his price target for the shares to DKK 275 from DKK 300. The analyst believes the company’s pipeline represents downside risk.
Subscribe to:
Posts (Atom)